 |
|
Blood test predicts sickle cell disease complication, identifies patients at high risk of death
July 19, 2006Hormone called BNP detects pulmonary hypertension
A team of scientists with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has found that a hormone detected in a simple blood test can identify patients with sickle cell disease who have developed a life-threatening complication called pulmonary hypertension. The team has also found that the same hormone is a clear predictor of death in adult sickle cell patients.
The hormone, called brain natriuretic peptide or BNP, is released by the heart ventricles and helps predict death in heart failure patients. The new study is published in the July 19 issue of the Journal of the American Medical Association.
"This is an important leap forward in research on sickle cell disease," said NHLBI Director Elizabeth G. Nabel, M.D. "Having a marker in the blood that will not only help identify sickle cell patients with this deadly complication but also predict those at the highest risk â€" will aid in the care and treatment of these patients."
Sickle cell anemia is one of the most common genetic blood disorders in the United States. About 30 percent of sickle cell patients have pulmonary hypertension. In this condition, there is constant high blood pressure in the pulmonary arteries that supply the lungs. This pressure leads to narrowed arteries, causing the heart to work harder to pump blood. Pulmonary hypertension often leads to heart failure and it is a major risk factor for death in adults with sickle cell disease. Currently, echocardiograms and other heart tests are used to diagnose pulmonary hypertension, but there has not been a blood test to help detect the condition.
Previous research has found that in patients with pulmonary hypertension, higher levels of BNP are associated with greater pressure in the pulmonary arteries. NHLBI researchers theorized that BNP levels might also correlate with the severity of pulmonary hypertension and risk of death in sickle cell patients.
Lead scientist Roberto Machado, M.D., an investigator with NHLBI's Vascular Medicine Branch, and colleagues, including scientists in the NIH Clinical Center, measured BNP levels in 230 patients with sickle cell disease enrolled in the NIH Pulmonary Hypertension Screening Study between 2001 and 2005. In order to confirm a diagnosis of pulmonary hypertension, the patients were given echocardiograms and other measurements of heart function. BNP levels were also measured in 45 healthy African-American controls, since the disease is more prevalent in African-Americans.
The scientists found that high blood levels of BNP â€" greater than 160 pg/mL â€" in these patients independently predicted mortality, increasing the risk of death by as high as fivefold.
The team also found that BNP levels could help identify the patients with pulmonary hypertension. NIH study patients who had a BNP of 160 pg/mL or higher had a 78 percent chance of having pulmonary hypertension identified by echocardiogram.
"We now have another tool to help diagnose pulmonary hypertension," Machado said. "There is tremendous value in diagnosing this deadly complication early and accurately so we can aggressively treat the complication and try to improve the patientâ€TMs outcome."
To validate and confirm the findings, the team then measured BNP levels in 121 stored blood samples from patients who had been enrolled in a sickle cell drug treatment study, the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Follow-up Study which began in 1996. These patients came from major sickle cell centers around the United States and at the time of enrollment it was not known that pulmonary hypertension was a common complication of sickle cell disease.
Thirty percent of patients in the MSH study had a BNP level greater than 160 pg/ml, consistent with a diagnosis of pulmonary hypertension. Most importantly, these patients had a threefold increased risk of death compared with patients without pulmonary hypertension.
"The MSH analysis validated the connection between high BNP blood levels, pulmonary hypertension and risk of death, found in the NIH study patients," said Mark Gladwin, M.D., chief of NHLBIâ€TMs Vascular Medicine Branch. "It also revealed that almost a third of sickle cell patients in the 1996 MSH study had undiagnosed pulmonary hypertension. Perhaps the most intriguing finding, these data suggest that it is pulmonary hypertension - not painful crises or acute chest syndrome â€" that is the major risk factor for death in adults with sickle cell disease." Acute chest syndrome is a life-threatening problem similar to pneumonia.
Sickle cell disease affects about 1 in 600 African-Americans and 1 in 1,000 to 1,400 Hispanic newborns every year. Patients with this disease have abnormal hemoglobin molecules in their red blood cells. The molecules damage the red cells, causing them to stick to blood vessel walls and resulting in pain, organ damage, and anemia.
With the development of new treatments for the symptoms and complications of sickle cell disease, patient survival has improved in recent years.
Machado is optimistic regarding the future outlook for sickle cell disease. "Based on these findings and other studies showing that pulmonary hypertension is a major risk factor for death in adult patients with sickle cell disease, there is great benefit to screening sickle cell patients with both echocardiography and blood BNP. By combining these tests, we hope to identify patients who can be treated more intensely to improve the management of their disease and hopefully their survival," he said.
Machado added that identifying these patients will bring them to the attention of scientists engaged in clinical trials of new treatments for the disease. He noted that NHLBI is currently participating in a multi-center study to test the safety and effectiveness of the drug bosentan in patients with sickle cell disease and pulmonary hypertension. An NHLBI-sponsored clinical trial studying the effects of sildenafil as a treatment for pulmonary hypertension in sickle cell disease is expected to begin recruiting patients early in 2007.
NIH/National Heart, Lung, and Blood Institute
"This is an important leap forward in research on sickle cell disease," said NHLBI Director Elizabeth G. Nabel, M.D. "Having a marker in the blood that will not only help identify sickle cell patients with this deadly complication but also predict those at the highest risk â€" will aid in the care and treatment of these patients."
Sickle cell anemia is one of the most common genetic blood disorders in the United States. About 30 percent of sickle cell patients have pulmonary hypertension. In this condition, there is constant high blood pressure in the pulmonary arteries that supply the lungs. This pressure leads to narrowed arteries, causing the heart to work harder to pump blood. Pulmonary hypertension often leads to heart failure and it is a major risk factor for death in adults with sickle cell disease. Currently, echocardiograms and other heart tests are used to diagnose pulmonary hypertension, but there has not been a blood test to help detect the condition.
Previous research has found that in patients with pulmonary hypertension, higher levels of BNP are associated with greater pressure in the pulmonary arteries. NHLBI researchers theorized that BNP levels might also correlate with the severity of pulmonary hypertension and risk of death in sickle cell patients.
Lead scientist Roberto Machado, M.D., an investigator with NHLBI's Vascular Medicine Branch, and colleagues, including scientists in the NIH Clinical Center, measured BNP levels in 230 patients with sickle cell disease enrolled in the NIH Pulmonary Hypertension Screening Study between 2001 and 2005. In order to confirm a diagnosis of pulmonary hypertension, the patients were given echocardiograms and other measurements of heart function. BNP levels were also measured in 45 healthy African-American controls, since the disease is more prevalent in African-Americans.
The scientists found that high blood levels of BNP â€" greater than 160 pg/mL â€" in these patients independently predicted mortality, increasing the risk of death by as high as fivefold.
The team also found that BNP levels could help identify the patients with pulmonary hypertension. NIH study patients who had a BNP of 160 pg/mL or higher had a 78 percent chance of having pulmonary hypertension identified by echocardiogram.
"We now have another tool to help diagnose pulmonary hypertension," Machado said. "There is tremendous value in diagnosing this deadly complication early and accurately so we can aggressively treat the complication and try to improve the patientâ€TMs outcome."
To validate and confirm the findings, the team then measured BNP levels in 121 stored blood samples from patients who had been enrolled in a sickle cell drug treatment study, the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Follow-up Study which began in 1996. These patients came from major sickle cell centers around the United States and at the time of enrollment it was not known that pulmonary hypertension was a common complication of sickle cell disease.
Thirty percent of patients in the MSH study had a BNP level greater than 160 pg/ml, consistent with a diagnosis of pulmonary hypertension. Most importantly, these patients had a threefold increased risk of death compared with patients without pulmonary hypertension.
"The MSH analysis validated the connection between high BNP blood levels, pulmonary hypertension and risk of death, found in the NIH study patients," said Mark Gladwin, M.D., chief of NHLBIâ€TMs Vascular Medicine Branch. "It also revealed that almost a third of sickle cell patients in the 1996 MSH study had undiagnosed pulmonary hypertension. Perhaps the most intriguing finding, these data suggest that it is pulmonary hypertension - not painful crises or acute chest syndrome â€" that is the major risk factor for death in adults with sickle cell disease." Acute chest syndrome is a life-threatening problem similar to pneumonia.
Sickle cell disease affects about 1 in 600 African-Americans and 1 in 1,000 to 1,400 Hispanic newborns every year. Patients with this disease have abnormal hemoglobin molecules in their red blood cells. The molecules damage the red cells, causing them to stick to blood vessel walls and resulting in pain, organ damage, and anemia.
With the development of new treatments for the symptoms and complications of sickle cell disease, patient survival has improved in recent years.
Machado is optimistic regarding the future outlook for sickle cell disease. "Based on these findings and other studies showing that pulmonary hypertension is a major risk factor for death in adult patients with sickle cell disease, there is great benefit to screening sickle cell patients with both echocardiography and blood BNP. By combining these tests, we hope to identify patients who can be treated more intensely to improve the management of their disease and hopefully their survival," he said.
Machado added that identifying these patients will bring them to the attention of scientists engaged in clinical trials of new treatments for the disease. He noted that NHLBI is currently participating in a multi-center study to test the safety and effectiveness of the drug bosentan in patients with sickle cell disease and pulmonary hypertension. An NHLBI-sponsored clinical trial studying the effects of sildenafil as a treatment for pulmonary hypertension in sickle cell disease is expected to begin recruiting patients early in 2007.
NIH/National Heart, Lung, and Blood Institute
Sickle Cell Current Events and Sickle Cell News RSSCausative gene of a rare disorder discovered by sequencing only protein-coding regions of genome
For the first time, scientists have successfully used a method called exome sequencing to quickly discover a previously unknown gene responsible for a mendelian disorder.
Drug shows promise in treating dangerous complication of erectile disorder
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston.
That '4 hour erection': new discovery may help prevent a complication of priapism
For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope.
Governor recognizes stem cell research at Einstein
Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today.
Males May Experience Greater Physical Pain Due To Lower Levels Of A Key Protein, Endothelin
Agonizing physical pain, known as vaso-occlusive pain, can afflict children who have sickle cell disease (SCD).
Faster, cheaper way to find disease genes in human genome passes initial test
University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links.
Mother's immune system may block fetal treatments for blood diseases
Pediatric researchers have resolved an apparent contradiction in the field of prenatal cell transplantation- a medical approach that holds future promise in correcting sickle cell disease and other serious congenital blood disorders.
NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns.
Children's Hospital Oakland scientists first to discover new source for harvesting stem cells
A groundbreaking study conducted by Children's Hospital & Research Center Oakland is the first to reveal a new avenue for harvesting stem cells from a woman's placenta, or more specifically the discarded placentas of healthy newborns.
Embryo's heartbeat drives blood stem cell formation
Biologists have long wondered why the embryonic heart begins beating so early, before the tissues actually need to be infused with blood.
More Sickle Cell Current Events and Sickle Cell News Articles
 |
Uncertain Suffering: Racial Health Care Disparities and Sickle Cell Disease (George Gund Foundation Imprint in African American Studies) by Carolyn Rouse (Author) On average, black Americans are sicker and die earlier than white Americans. Uncertain Suffering provides a richly nuanced examination of what this fact means for health care in the United States through the lens of sickle cell anemia, a disease that primarily affects blacks. In a wide ranging analysis that moves from individual patient cases to the compassionate yet distanced professionalism of health care specialists to the level of national policy, Carolyn Moxley Rouse uncovers the cultural assumptions that shape the quality and delivery of care for sickle cell patients. She reveals a clinical world fraught with uncertainties over how to treat black patients given resource limitations and ambivalence. Her book is a compelling look at the ways in which the politics of racism, attitudes... |
 |
To All My Friends on Shore Starring: Gloria Foster, Dennis Hines, Bill Cosby, Dennis Pate, Ray Mason Directed By: Gilbert Cates Also With: Bill Cosby (Composer), Urs B. Furrer (Cinematographer), Angelo Ross (Editor) An touching heartwarming slice of life story about a hard working airport redcap (Bill Cosby) dreams of getting his son, Vandy (Dennis Hines) and his wife, Serera (Gloria Foster The Matrix) out of the ghetto and into a home of there own, only to discover |
 |
Understanding Sickle Cell Disease (Understanding Health and Sickness Series) by Ph.D., Miriam Bloom (Author) |
|
The Sickle Cell Slime-O-Rama Game by lookoutmedia | |
 |
Sickle Cell JR Perry (Primary Contributor) |
 |
Sickle Cell Anemia Awareness Ribbon Mouse Pad by MyHeritageWear.com The Sickle Cell Anemia Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Sickle Cell Anemia Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Sickle Cell Anemia Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
ProntoPass Naplex Review Sickle Cell Anemia Poster by ProntoPass Solutions NAPLEX® Review Poster on Sickle Cell Anemia. This Poster includes symptoms, treatments, complications, Hemoglobins and more. All ProntoPass® posters are scored for easy folding and drilled for easy hanging. |
|
Sickle Cell Mix (Tea) by The Herbal Gardens of South Florida Inc. | |
 |
Chromosome 11 Gene Therapy Sickle Cell Anemia Photographic Poster Print, 24x32 by Art.com Art.com is the world's largest retailer of art prints, posters, photographs, and framed artwork. With our huge selection of over 400,000 prints, you'll easily find the perfect piece for your home, office, or classroom. Our art is printed on quality paper. When you order framed artwork, the piece is built by our team of in-house professionals. Visit our Amazon store today at www.amazon.com/artdotcom to find Special Offers and search for products based on 'Artist Name' and 'Subject Categories' such as Movie, Music, Vintage, TV, Children, Travel, Kitchen, Museum Art, Animals, Floral, Motivational, and Sports. Art.com is dedicated to providing you with high quality products and service by offering you 100% satisfaction guaranteed. We ship internationally to over 80 countries. Decorate your... |
 |
Dream Runner Also With: Warner Bros. (Producer) |
| © 2009 BrightSurf.com |